Mohamad Mohty, MD, PHD, a professor of hematology at Saint-Antoine Hospital and University Pierre & Marie Curie, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.
Efficacy and safety data have been seen in a number of areas, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma (NHL), and multiple myeloma. Mohty says the results are more consolidated with very recent follow-up and promising survival curves.
Furthermore, Mohty says that some trials are investigating third and fourth generation CAR T cells and looking at other targets, including dual targets. The CAR T cells are not only impacting the relapsed/refractory setting of these diseases, but they are also moving to the frontline, such as in myeloma and NHL.
For more resources and information regarding anticancer targeted therapies in hematology: [ Ссылка ]
